MoonLake's Sonelokimab Achieves 62% HiSCR75 Response at 40 Weeks—Setting a New Benchmark in Hidradenitis Suppurativa Clinical Trials
Market Chameleon (Mon, 30-Mar 9:18 AM)
MoonLake’s Sonelokimab Shows Over 80% Patient Improvement in Phase 2 axSpA Trial, Bolstering Pipeline Strength
Market Chameleon (Mon, 23-Feb 7:06 AM)
Fast Track Designation Positions MoonLake’s Sonelokimab for Accelerated Path in PPP as Major 2026 Milestones Approach
Market Chameleon (Mon, 2-Feb 8:42 AM)
